From tackling COVID-19 variants to therapeutic discovery, novel organoids and more, advance your assay research with these exclusive interviews and free resources
Dr. Erik Tillman shares his virtual company’s quest to find an effective new life-changing treatment for non-alcoholic steatohepatitis
The Simple Plex AAV2 assay combines the scalability and automation of Ella with best-in-class AAV reagents from PROGEN
The company seeks to become a global centre of excellence for whole genome sequencing
Dr. Dallas Flies, Vice President, Discovery Research, NextCure, Inc. discusses the cutting-edge technology transforming the identification of new targets for the development of effective immunotherapeutics
Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models
Team at the Karl Landsteiner University of Health Sciences in Krems identifies strong correlation between cachexia and markers of bone loss
Leading clinical laboratory runs first-ever successful automation of a CRISPR test for high-throughput, using Sherlock’s SARS-CoV-2 process
Clinical microbiology and virology expert shares her formula for success when diagnosing and treating conditions such as meningitis and encephalitis
Scientists at University of Warwick demonstrate that levels of a protein – TPD54 – affect movement of cells
Researchers found that longer dosing intervals led to higher antibody levels and a higher proportion of ‘helper’ T cells
Findings explain higher risk of heart attack in people with diabetes, even after treatment
The drug aims to treat patients with myelodysplastic syndromes
The multiplex PCR test is capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases
The High Throughput Tissector (HT) delivers faster, more accurate and efficient tissue dissection
Immune repertoire assays offer high detection rates of malignant clones, empowering researchers to better assess blood cancers
Study finds switches near GDF5 gene linked to knee osteoarthritis, hip dysplasia
The investment will scale Sweetch’s Just-In-Time-Adaptive-Intervention (JITAI) technology to help each individual adhere to their treatment programs and improve clinical outcomes
